实用药物与临床
實用藥物與臨床
실용약물여림상
PRACTICAL PHARMACY AND CLINICAL REMEDIES
2015年
5期
622-624
,共3页
2型糖尿病%西格列汀%二肽基肽酶抑制剂%B细胞
2型糖尿病%西格列汀%二肽基肽酶抑製劑%B細胞
2형당뇨병%서격렬정%이태기태매억제제%B세포
Type 2 diabetes%Sitagliptin%Dipeptide peptidase inhibitors%B cell
目的:研究西格列汀对初发2型糖尿病患者胰岛B细胞功能的影响。方法选择我院门诊2型糖尿病患者69例,随机分为对照组和试验组,对照组35例,试验组34例,对照组予二甲双胍治疗,试验组予二甲双胍、西格列汀治疗,12周后比较治疗前后两组患者空腹血糖( FPG )、餐后2 h 血糖( PPG )、糖化血红蛋白(HbA1c)、体重指数(BMI)、空腹胰岛素(Fins)、餐后2 h胰岛素(Pins)。结果两组治疗前各项指标比较差异无统计学意义(P>0.05),治疗后,两组FPG、PPG、HbA1c、BMI均较治疗前显著下降(P<0.05)。与对照组相比,试验组FPG、PPG、HbA1c降低更明显(P<0.05),Fins、Pins水平升高更显著(P<0.05)。结论西格列汀能明显改善初发2型糖尿病患者的胰岛B细胞功能,在临床应用中安全有效。
目的:研究西格列汀對初髮2型糖尿病患者胰島B細胞功能的影響。方法選擇我院門診2型糖尿病患者69例,隨機分為對照組和試驗組,對照組35例,試驗組34例,對照組予二甲雙胍治療,試驗組予二甲雙胍、西格列汀治療,12週後比較治療前後兩組患者空腹血糖( FPG )、餐後2 h 血糖( PPG )、糖化血紅蛋白(HbA1c)、體重指數(BMI)、空腹胰島素(Fins)、餐後2 h胰島素(Pins)。結果兩組治療前各項指標比較差異無統計學意義(P>0.05),治療後,兩組FPG、PPG、HbA1c、BMI均較治療前顯著下降(P<0.05)。與對照組相比,試驗組FPG、PPG、HbA1c降低更明顯(P<0.05),Fins、Pins水平升高更顯著(P<0.05)。結論西格列汀能明顯改善初髮2型糖尿病患者的胰島B細胞功能,在臨床應用中安全有效。
목적:연구서격렬정대초발2형당뇨병환자이도B세포공능적영향。방법선택아원문진2형당뇨병환자69례,수궤분위대조조화시험조,대조조35례,시험조34례,대조조여이갑쌍고치료,시험조여이갑쌍고、서격렬정치료,12주후비교치료전후량조환자공복혈당( FPG )、찬후2 h 혈당( PPG )、당화혈홍단백(HbA1c)、체중지수(BMI)、공복이도소(Fins)、찬후2 h이도소(Pins)。결과량조치료전각항지표비교차이무통계학의의(P>0.05),치료후,량조FPG、PPG、HbA1c、BMI균교치료전현저하강(P<0.05)。여대조조상비,시험조FPG、PPG、HbA1c강저경명현(P<0.05),Fins、Pins수평승고경현저(P<0.05)。결론서격렬정능명현개선초발2형당뇨병환자적이도B세포공능,재림상응용중안전유효。
Objective To explore the effect of sitagliptin on B cell function in the treatment of newly diag-nosed type 2 diabetes. Methods 69 outpatients with type 2 diabetes in our hospital were randomly divided into control group (n=35) and trial group (n=34),patients were treated with metformin without or with sitagliptin respectively. Two groups were followed up for 12 weeks. Fasting plasma glucose ( FPG) ,2 h postprandial plasma glucose ( PPG) , glycosylated hemoglobin (HbA1c),change in body mass index (BMI),fasting plasma insulin (Fins),2 h postprandial plasma insulin ( Pins) were recorded in the two groups before and after treatment. Results There was no significant difference between the two groups in FPG,PPG,HbA1c,BMI,Fins,Pins before treatment (P>0. 05). Compared with the baseline,FPG,PPG,HbA1c,BMI in both two groups declined significantly (P <0. 05). After treatment,FPG, PPG,HbA1c were significantly lower,and Fins,Pins were significantly higher in treatment group compared with those in control group (P<0. 05). Conclusion Sitagliptin could obviously improve B cell function in the treatment of new-ly diagnosed type 2 diabetes,it is safe and effective in clinical application.